A Phase III Study to Evaluate the Immunogenicity and Safety of GC1107 (Adult Tetanus Diphtheria Vaccine) in Healthy Adults

Jacob Lee, Jung-Hyun Choi, Seong-Heon Wie, Sun Hee Park, Su-Mi Choi, Mi Suk Lee, Tae Hyong Kim, Hyo-Jin Lee, Jin Han Kang, Jacob Lee, Jung-Hyun Choi, Seong-Heon Wie, Sun Hee Park, Su-Mi Choi, Mi Suk Lee, Tae Hyong Kim, Hyo-Jin Lee, Jin Han Kang

Abstract

Background: This study was conducted to assess the immunogenicity and safety of GC1107 (adult tetanus diphtheria [Td] vaccine). The primary goal was to evaluate the non-inferiority of the immunogenicity of GC1107 compared to the control vaccine. Additionally, the safety profiles of GC1107 and the control vaccine were compared.

Methods: The subjects were adults ≥ 18 years old who were not injected with Td or adult tetanus-diphtheria-pertussis (TdaP) vaccine within the recent 5 years. A total of 253 subjects were enrolled and randomized to either the GC1107 group or the control group. For immunogenicity assessment, blood samples were collected at baseline and 28 days after vaccination and antibody titer of diphtheria and tetanus were assessed.

Results: The seroprotection rates of diphtheria and tetanus were 89.76% and 91.34%, respectively, in the GC1107 group, and 87.80% and 86.99% in the control group. The geometric mean titer (GMT) of the anti-diphtheria antibody increased after vaccination in both groups, showing no significant difference between the groups (P = 0.139). The anti-tetanus GMTs after vaccination also showed comparable increases in both groups, and showed no significant difference (P = 0.860). In the safety evaluation, solicited local adverse reactions occurred in 81.2% of the subjects in the GC1107 group and in 86.4% of the subjects in the control group. Solicited systemic adverse events occurred in 33.2% of the subjects in the GC1107 group and in 47.2% of the subjects in the control group, which did not reach statistical significance.

Conclusion: This phase III study demonstrated non-inferiority in immunogenicity and comparable safety of GC1107 compared with the control Td vaccine.

Trial registration: ClinicalTrials.gov Identifier: NCT02361866.

Keywords: Immunogenicity; Safety; Td; Vaccine.

Conflict of interest statement

Disclosure: The authors have no potential conflicts of interest to disclose.

Figures

Fig. 1. Participation status of the clinical…
Fig. 1. Participation status of the clinical study subjects.

References

    1. Tiwari TS, Wharton M. Diphtheria toxoid. In: Plotkin SA, Orsentein WA, Offit PA, Edwards KM, editors. Plotkin's Vaccines. 7th ed. Philadelphia, PA: Elsevier; 2018. pp. 261–275.
    1. Roper MH, Wassilak SG, Scobie HM, Ridpath AD, Orenstein WA. Tetanus toxoid. In: Plotkin SA, Orsentein WA, Offit PA, Edwards KM, editors. Plotkin's Vaccines. 7th ed. Philadelphia, PA: Elsevier; 2018. pp. 1052–1080.
    1. Lee SY, Kim JS, Ahn JH, Choi JH, Ma SH, Park JS, et al. Immunoassay of diphtheria and tetanus according to ages. Infect Chemother. 2012;44(2):62–66.
    1. Hamborsky J, Kroeger A, Wolfe S. Epidemiology and Prevention of Vaccine-preventable Diseases. 13th ed. Washington, D.C.: Centers for Disease Control and Prevention; 2015.
    1. Hardy IR, Dittmann S, Sutter RW. Current situation and control strategies for resurgence of diphtheria in newly independent states of the former Soviet Union. Lancet. 1996;347(9017):1739–1744.
    1. Kang JH. The need of Td vaccination according to the changes of tetanus and diphtheria Immunity. J Korean Med Assoc. 2008;51(2):127–136.
    1. Kang JH, Hur JK, Kim JH, Lee KI, Park SE, Ma SH, et al. Age related seroepidemiological study of diphtheria among Koreans. Korean J Infect Dis. 2000;32(1):1–7.
    1. Kang JH, Hur JK, Kim JH, Lee KI, Park SE, Ma SH, et al. Age related serosurvey of immunity to tetanus in Korean populations. Korean J Infect Dis. 2001;33(2):104–111.
    1. Sung H, Jang MJ, Bae EY, Han SB, Kim JH, Kang JH, et al. Seroepidemiology of tetanus in Korean adults and adolescents in 2012. J Infect Chemother. 2014;20(7):397–400.
    1. Lee SY, Kwak GY, Mok HR, Kim JH, Hur JK, Lee KI, et al. The immunogenicity and reactogenicity of Td booster vaccination in Korean preadolescents, aged 11-12 years old. Korean J Pediatr. 2008;51(11):1185–1190.
    1. Lee SY, Kwak GY, Nam CH, Kim JH, Hur JK, Lee KY, et al. Immunogenicity and safety of diphtheria-tetanus vaccine in pre-adolescent and adolescent South Koreans. Vaccine. 2009;27(24):3209–3212.
    1. Choi JH, Choo EJ, Huh A, Choi SM, Eom JS, Lee JS, et al. Immunogenicity and safety of diphtheria-tetanus vaccine in adults. J Korean Med Sci. 2010;25(12):1727–1732.
    1. Choi JH, Kang JH. Tetanus, diphtheria, pertussis. In: Cheong HJ, Kim ES, Choi YH, Choi WS, Choi JH, Choi HJ, et al., editors. Vaccination for Adult. 2nd ed. Seoul, Korea: MIP Press; 2012. pp. 189–204.
    1. Lee HJ, Choi JH. Tetanus-diphtheria-acellular pertussis vaccination for adults: an update. Clin Exp Vaccine Res. 2017;6(1):22–30.
    1. Shin DH, Yu HS, Park JH, Shin JH, Kim SJ. Recently occurring adult tetanus in Korea: emphasis on immunization and awareness of tetanus. J Korean Med Sci. 2003;18(1):11–16.
    1. Lu PJ, O'Halloran A, Ding H, Liang JL, Williams WW. National and state-specific Td and TdaP vaccination of adult populations. Am J Prev Med. 2016;50(5):616–626.
    1. Kanitz EE, Wu LA, Giambi C, Strikas RA, Levy-Bruhl D, Stefanoff P, et al. Variation in adult vaccination policies across Europe: an overview from VENICE network on vaccine recommendations, funding and coverage. Vaccine. 2012;30(35):5222–5228.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner